| Non-syndromic Hirschsprung's disease as a result of a RET gene variant. | Non-syndromic Hirschsprung's disease as a result of a RET gene variant.
Gietz R, Armando R, Lobos P, Liberto D. | 04/22/2024 |
| Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement. | Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M, Xu ZX, Dai M, Zhu YY. | 04/12/2024 |
| Accelerated MEN2A in homozygous RET carriers in the context of consanguinity. | Accelerated MEN2A in homozygous RET carriers in the context of consanguinity.
Machens A, Dralle H. | 03/26/2024 |
| Aberrant SOX10 and RET expressions in patients with Hirschsprung disease. | Aberrant SOX10 and RET expressions in patients with Hirschsprung disease.
Gunadi, Amadeus VC, Utami FDT, Halim FV, Novebri NA, Hanggoro RA, Lestari AN, Iskandar K, Dwihantoro A, Purnomo E., Free PMC Article | 03/18/2024 |
| RET Signaling Persists in the Adult Intestine and Stimulates Motility by Limiting PYY Release From Enteroendocrine Cells. | RET Signaling Persists in the Adult Intestine and Stimulates Motility by Limiting PYY Release From Enteroendocrine Cells.
Shepherd A, Feinstein L, Sabel S, Rastelli D, Mezhibovsky E, Matthews L, Muppirala A, Robinson A, Sharma KR, ElSeht A, Zeve D, Breault DT, Gershon MD, Rao M., | 02/26/2024 |
| GDF-15 Inhibits ADP-Induced Human Platelet Aggregation through the GFRAL/RET Signaling Complex. | GDF-15 Inhibits ADP-Induced Human Platelet Aggregation through the GFRAL/RET Signaling Complex.
Xie B, Tang W, Wen S, Chen F, Yang C, Wang M, Yang Y, Liang W., Free PMC Article | 02/12/2024 |
| Impact of the overexpression of the tyrosine kinase receptor RET in the hematopoietic potential of induced pluripotent stem cells (iPSCs). | Impact of the overexpression of the tyrosine kinase receptor RET in the hematopoietic potential of induced pluripotent stem cells (iPSCs).
Marcoux P, Imeri J, Desterke C, Latsis T, Chaker D, Hugues P, Griscelli AB, Turhan AG. | 01/10/2024 |
| Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts. | Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY, Li RZ, Wang DX, Liu H, Tian J, Ding ZN, Yan LJ, Dong ZR, Hong JG, Tian BW, Han CL, Zhao HT, Li T. | 01/4/2024 |
| Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study. | Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study.
Rosenblum RC, Hirsch D, Grozinsky-Glasberg S, Benbassat C, Yoel U, Ishay A, Zolotov S, Bachar G, Banne E, Levy S, Twito O., Free PMC Article | 12/4/2023 |
| Thirty Years of Progress Thanks to the RET Oncogene. | Thirty Years of Progress Thanks to the RET Oncogene.
Castinetti F, Borson-Chazot F. | 11/21/2023 |
| Letter to the Editor: The Somatic RET M918T Variant May Modify the Natural History of Germline RET L790F MEN2-Related Medullary Thyroid Carcinoma. | Letter to the Editor: The Somatic RET M918T Variant May Modify the Natural History of Germline RET L790F MEN2-Related Medullary Thyroid Carcinoma.
Sahakian N, Romanet P, Mirebeau-Prunier D, Paladino C, Castinetti F, Barlier A. | 11/16/2023 |
| Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy. | Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA, Basilaia M, Kim W, Getz T, Gustafson JL, Zage PE., | 10/11/2023 |
| TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation. | TMEM127 suppresses tumor development by promoting RET ubiquitination, positioning, and degradation.
Guo Q, Cheng ZM, Gonzalez-Cantú H, Rotondi M, Huelgas-Morales G, Ethiraj P, Qiu Z, Lefkowitz J, Song W, Landry BN, Lopez H, Estrada-Zuniga CM, Goyal S, Khan MA, Walker TJ, Wang E, Li F, Ding Y, Mulligan LM, Aguiar RCT, Dahia PLM., Free PMC Article | 10/10/2023 |
| Germline founder variant c.1998delinsTTCT in the RET oncogene: a cohort study in 15 Belgian families. | Germline founder variant c.1998delinsTTCT in the RET oncogene: a cohort study in 15 Belgian families.
Vuylsteke A, Hannes L, Brems H, Devis K, Renard M, Uyttebroeck A, Legius E, Decallonne B. | 09/22/2023 |
| RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients. | RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients.
Khonrak T, Watcharadetwittaya S, Chamgramol Y, Intarawichian P, Deenonpoe R., Free PMC Article | 05/20/2023 |
| High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer. | High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer.
Kakati RT, Kim H, Whitman A, Spanheimer PM., Free PMC Article | 05/20/2023 |
| RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape. | RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S, Califano R, Reinmuth N, Tamma A, Puri T., Free PMC Article | 05/12/2023 |
| Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma. | Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma.
Werner RA, Sayehli C, Hänscheid H, Higuchi T, Serfling SE, Fassnacht M, Goebeler ME, Buck AK, Kroiss M., Free PMC Article | 04/27/2023 |
| RET signaling in breast cancer therapeutic resistance and metastasis. | RET signaling in breast cancer therapeutic resistance and metastasis.
Pecar G, Liu S, Hooda J, Atkinson JM, Oesterreich S, Lee AV., Free PMC Article | 03/19/2023 |
| ["Graded early warning system" of RET germline mutation carriers in MEN2A/MEN2B families and total thyroidectomy (report of 7 cases)]. | ["Graded early warning system" of RET germline mutation carriers in MEN2A/MEN2B families and total thyroidectomy (report of 7 cases)].
Qi XM, Li WX, Huang JW, Huang ZG, Chen XH. | 03/13/2023 |
| RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. | RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A, Miranda-Morales E, den Hollander P, Friedlaender A, O Sintim H, Wu J, Mani SA, Subbiah V., Free PMC Article | 03/2/2023 |
| GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1. | GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.
Marks BA, Pipia IM, Mukai C, Horibata S, Rice EJ, Danko CG, Coonrod SA., Free PMC Article | 02/25/2023 |
| Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations. | Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
Cao S, Tan C, Fei A, Hu G, Fu M, Lv J. | 01/11/2023 |
| RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges. | RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A, Esposito D, Ferrara R, Signorelli D, Belli S, Napolitano F, Santaniello A, Ciciola P, Formisano L, Bianco R. | 11/26/2022 |
| Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A. | Unexpected structures formed by the kinase RET C634R mutant extracellular domain suggest potential oncogenic mechanisms in MEN2A.
Liu Y, De Castro Ribeiro O, Haapanen O, Craven GB, Sharma V, Muench SP, Goldman A., Free PMC Article | 11/19/2022 |